Bioglan and Stada partner to increase capacity to meet rising demand for Parkinson’s treatment
15 November 2021
- REIG JOFRE’s Bioglan subsidiary in Sweden and STADA are investing EUR3 million to expand Bioglan’s facilities with a highly technological production line devoted to a patented combination therapy for Parkinson’s disease
- Bioglan is the exclusive manufacturer for the European market of the medicine, which is marketed by STADA as a treatment indicated for advanced Parkinson’s disease
- The therapy has already been approved in several European countries and is currently marketed by STADA in Nordic countries, Germany, Austria, and Slovenia, with further launches imminent